title: Disseminated herpes simplex virus type-1 infection in long-term usage of everolimus.
authors.forename: Monji
authors.initials: M
authors.lastname: Koga
authors.forename: Ichiro
authors.initials: I
authors.lastname: Nakayama
authors.forename: Teppei
authors.initials: T
authors.lastname: Sakai
authors.forename: Kaori
authors.initials: K
authors.lastname: Koga
authors.forename: Shinichi
authors.initials: S
authors.lastname: Imafuku
authors.forename: Juichiro
authors.initials: J
authors.lastname: Nakayama
mesh_terms: D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D004359:Drug Therapy, Combination; D000068338:Everolimus; D006561:Herpes Simplex / Q000175:diagnosis / Q000209:etiology*; D018259:Herpesvirus 1, Human / Q000302:isolation & purification / Q000502:physiology*; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017193:Skin Diseases, Viral / Q000175:diagnosis / Q000209:etiology*; D013997:Time Factors; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D011239:Prednisolone; D020123:Sirolimus